Bendeka

BENDEKA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy relative to first-line therapies other than chlorambucil has not been established. BENDEKA is... prescribed to treat 2 types of cancer: If you have been diagnosed with CLL, you may receive BENDEKA If you have been previously treated for NHL that has continued to worsen during or after treatment with another medication, your doctor may switch you to BENDEKA Treating blood cancer is a journey. Depending on where you are in your journey, your oncologist may prescribe BENDEKAa type of chemotherapy. Chemotherapy is a chemical treatment that uses drugs to stop the growth of cancer cells. It does this either by killing the cells or by stopping them from growing in number. BENDEKA is not right for everyone, including patients with a known allergic response to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol. BENDEKA may cause serious side effects including: low blood cell counts, infections or recurrence of infections, unexpected responses to BENDEKA when placed in your blood, sudden and severe allergic responses, kidney failure due to fast breakdown of cancer cells, other cancers, and leaking of BENDEKA out of your vein and into your surrounding skin. Some of these side effects, such as low blood counts, infections, liver injury, and severe allergic skin responses (when bendamustine HCl was given alone and in combination with other anticancer medications or allopurinol), have caused death. Tell your doctor if you have any side effects including: rash, facial swelling, or difficulty breathing during or soon after your infusion with BENDEKA injection. These are signs of an allergic reaction. You also should tell your doctor if you have shortness of breath, significant fatigue, bleeding, bruising, fever, or other signs of infection. Also, ...Read More